Summary of findings 4. Paroxetine compared with aprepitant for depression.
| paroxetine compared with aprepitant for depression | ||||||
| Patient or population: patients with depression Settings: in‐ and out‐patients Intervention: paroxetine Comparison: aprepitant | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Aprepitant | Paroxetine | |||||
| Failure to respond at endpoint (6‐12 weeks) | See comment | See comment | See comment | 0 (0) | See comment | No trial reported this outcome. |
| Failure to respond at 1‐4 weeks | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| Failure to respond at 16‐24 weeks | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| Failure to remit at endpoint | 444 per 1000 | 557 per 1000 (464 to 647) | OR 1.57 (1.08 to 2.29) | 807 (4 studies) | ⊕⊕⊕⊕ high | |
| SMD at endpoint | The mean SMD at endpoint in the intervention groups was 0.00 standard deviations higher (0.39 lower to 0.39 higher) | 102 (1 study) | ⊕⊕⊕⊕ high | This correspond to no treatment effect. | ||
| Failure to complete ‐ any cause ‐ | 282 per 1000 | 375 per 1000 (230 to 548) | OR 1.53 (0.76 to 3.09) | 143 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Participants with at least some Side Effects | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; SMD: standardized mean difference; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Blinding stated but not tested. No information on randomisation procedures and allocation concealment.